The popularity of pharmaceutical and bio IPO stocks withers … Why is the cold investment open?



[사진=픽사베이]
[사진=픽사베이]

New pharmaceutical and biotech stocks with less than 100 to 1 competition

Recently, the enthusiasm for investment in pharmaceutical and biotech companies that are trying to be listed on the stock market has cooled down. Received an offer for public offerings for individual investors in the second half of the year Avion, Frombio, Tea Vaccine Research InstituteThe competition ratio was less than 100 to 1.

Genome analysis specialist GeninusAlso announced that it recorded a competition ratio of 162 to 1 in the general public offering held on the 27th and 28th. Personal funds were 812.5 billion won. The competition ratio for institutional investors was only 66 to 1. Geninus is scheduled to be listed on the KOSDAQ on the 9th of next month.

Geninus, a company that was spun off from the Genomics Research Center of Samsung Seoul Hospital, was evaluated to have failed to meet expectations as a company that succeeded in commercializing a clinical sequencing platform that analyzes cancer genomes and selects customized anticancer drugs for the first time in Korea.

In particular, Geninus received the subscription on the date of the refund of the Kakao Pay IPO shares. This has the effect of influencing the funds raised for the Kakao Pay subscription. However, compared to Kakao Pay, where 1.8 million individual investors invested 5,660.8 billion won, the results are poor.

Weizensell
Weizensell

Investing in new listed stocks, but rather a loss

This atmosphere was largely due to the sluggish stock prices of pharmaceutical and biotech companies, which were expected this year, after their listing. Boryung Pharmaceutical Group affiliated company specializing in immune cell therapy WeizensellThe individual shareholder competition ratio reached 886 to 1. However, the closing price on the 29th is 33,750 won, which is a 35% loss compared to the public offering price (52,700). It has been two months since the company was listed on August 25th.

manufactures and sells biocompatible fillers Bio PlusThe individual competition ratio reached 1206 to 1. However, the stock price fell to 25,700 won on that day, 19% lower than the public offering price (31,500 won) within a month of listing. in addition CHA Biotech, Frombio, Avion All of the recently listed stocks are trading at a price lower than the IPO price.

An official from the securities industry said, “Companies are focusing on Corona 19, and there are many cases where clinical trials and academic conferences have been suspended, so investor sentiment has contracted in bio companies that are not directly linked to Corona.”

He explained, “In terms of macroeconomics, the unstable exchange rate and rising consumer price index have a negative impact on the sustainable growth of the pharmaceutical industry due to the nature of the domestic pharmaceutical industry, which is highly dependent on imports of foreign drug substances and finished drugs.”

Large pharmaceutical affiliates plan to list one after another… Will the investment fever heat up?

In the future, the schedule of listing of pharmaceutical and bio companies is waiting one after another. Ildong Pharmaceutical Group affiliates Ildong Bioscienceis a company specializing in lactic acid bacteria. The market is in a steady growth trend and business areas using probiotics are also diversifying, so it is evaluated that the potential is very large.

Boryung Pharmaceutical Group followed by Vigencell Boryeong Biopharma listing is in progress. As a company specializing in vaccines, it is concentrating on expanding clinical trials of high value-added vaccines, securing original mRNA technology, and researching immune cell therapies.

Dongkuk Pharmaceutical aims for next year Dongguk Life Science preparing for listing. Huons Group is pursuing listings on Huons Medicare and Huons Biopharma, while Jeil Pharm is pursuing listing on its subsidiary Onconic Therapeutics.

Daewoong Pharmaceutical is a subsidiary IE TherapeuticsThe goal is to list the company by 2025. iN Therapeutics currently owns a non-narcotic analgesic ‘iN1011-N17’, as well as a treatment for hearing loss and a treatment for brain diseases.

The promotion of SME listing is also active. Cosmetic raw material development company using plant cell and bio-culture technology Bio FDNCas a new drug development company, including Future Medicineclass D&D PharmatechThe Korea Exchange has requested a preliminary examination for listing on the KOSDAQ.

Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited


Source: 헬스코리아뉴스 – 더뉴스 by www.hkn24.com.

*The article has been translated based on the content of 헬스코리아뉴스 – 더뉴스 by www.hkn24.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!